Abiraterone: all 195 studies that test it
Page 2 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerSuspendedNCT05361915Phase 2
- A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)TerminatedNCT05295927Phase 1
- Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.TerminatedNCT05276492Phase 1
- Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialActive, not recruitingNCT05223582Phase 2
- Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
- First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerActive, not recruitingNCT05189457Phase 2
- The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene MutationStatus unknownNCT05167175Phase 2
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate CancerActive, not recruitingNCT05067140Phase 1/2
- A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male VolunteersCompletedNCT04889651Phase 1
- Phase 1 Study of ATRS-2002 in Healthy Male AdultsWithdrawnNCT04879589Phase 1
- Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese VolunteersCompletedNCT04863105Phase 1
- Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerCompletedNCT04862091Phase 2
- Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)Active, not recruitingNCT04748042Phase 2
- Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the ProstateStatus unknownNCT04736108Phase 2
- Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese AdultsStatus unknownNCT04735913Early Phase 1
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04691804Phase 3
- Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerCompletedNCT04666129Phase 1
- A Study of CC-90011 and Comparators in Participants With Prostate CancerCompletedNCT04628988Phase 1
- A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerActive, not recruitingNCT04577833Phase 1
- Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1
- Abiraterone Acetate in Combination With TildrakizumabTerminatedNCT04458311Phase 1/2
- Oral EPI-7386 in Patients with Castration-Resistant Prostate CancerTerminatedNCT04421222Phase 1
- Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate CancerStatus unknownNCT04356430Phase 2
- Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on AbirateroneWithdrawnNCT04296578Phase 1
- A Study Designed to Evaluate the Pharmacokinetic Profile of AbirateroneCompletedNCT04295161Phase 1
- PK and Dose Escalation and Expansion Study of DST-2970TerminatedNCT04291664Phase 1
- Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate CancerActive, not recruitingNCT04267887Phase 2
- A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerActive, not recruitingNCT04194554Phase 1/2
- A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPCStatus unknownNCT04108247Phase 1
- Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate CancerCompletedNCT04056754Phase 3
- Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerActive, not recruitingNCT03902951Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCompletedNCT03860987Phase 2
- Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerActive, not recruitingNCT03821792Phase 2
- Androgen Reduction in Congenital Adrenal HyperplasiaWithdrawnNCT03548246Phase 2
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaActive, not recruitingNCT03436654Phase 2
- Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerTerminatedNCT03360721Phase 2
- Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the ProstateStatus unknownNCT03356444Phase 2
- Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelCompletedNCT03295565Phase 2/3
- Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC PatientsWithdrawnNCT03173859Phase 2
- Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaStatus unknownNCT03145285Phase 2
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownNCT03141671Phase 2
- Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerActive, not recruitingNCT03016741Phase 4
- Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsActive, not recruitingNCT03012321Phase 2
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerCompletedNCT03009981Phase 3
- A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
- Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPCCompletedNCT02913196Phase 1
- Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food IntakeCompletedNCT02883166Phase 1
- Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland CancersCompletedNCT02867852Phase 2
- Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone LevelsCompletedNCT02867020Phase 2
- Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerActive, not recruitingNCT02807805Phase 2
- Abiraterone-Rechallenge Study for CRPC PatientsTerminatedNCT02656615Phase 2
- Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSACompletedNCT02429193Phase 2
- Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate CancerCompletedNCT02415621Early Phase 1
- A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyCompletedNCT02405858Phase 4
- Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or AibrateroneWithdrawnNCT02380313Phase 1
- Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male ParticipantsCompletedNCT02230046Phase 1
- Neo-adjuvant Abiraterone Prostate StudyCompletedNCT02160353Phase 2
- A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyWithdrawnNCT02159690Phase 2
- Sequencing Abiraterone and Enzalutamide in mCRPCCompletedNCT02125357Phase 2
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02123758Phase 1
- Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)CompletedNCT02077634Phase 2
- A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic FunctionCompletedNCT02001571Phase 1
- Abiraterone Acetate for Castrate Resistant Prostate CancerCompletedNCT01961843Not applicable
- A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerActive, not recruitingNCT01957436Phase 3
- Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedNCT01913015Phase 1
- A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male ParticipantsCompletedNCT01873001Phase 1
- Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone AcetateCompletedNCT01858441Not applicable
- Abiraterone Acetate in Molecular Apocrine Breast CancerCompletedNCT01842321Phase 2
- Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast CancerWithdrawnNCT01814865Phase 2
- A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male PatientsCompletedNCT01798628Phase 1
- A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received DocetaxelCompletedNCT01795703Phase 2
- Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateCompletedNCT01792687Phase 1
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerActive, not recruitingNCT01786265Phase 2
- Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following SurgeryCompletedNCT01780220Phase 1/2
- A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate CancerCompletedNCT01756638Phase 2
- BKM120+Abiraterone Acetate for Metastatic CRPCTerminatedNCT01741753Phase 1
- A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal FunctionCompletedNCT01715259Phase 1
- A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone AcetateCompletedNCT01685268Phase 1/2
- A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male ParticipantsCompletedNCT01678573Phase 1
- An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001CompletedNCT01664728Phase 1
- A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male ParticipantsCompletedNCT01655147Phase 1
- A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial TabletCompletedNCT01640093Phase 1
- Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate CancerCompletedNCT01591122Phase 3
- A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult MenCompletedNCT01588782Phase 1
- A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese MenCompletedNCT01575587Phase 1
- XL-184+Abiraterone in Post-Chemo CRPCCompletedNCT01574937Phase 1
- A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase DeficiencyCompletedNCT01495910Phase 1
- A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult VolunteersCompletedNCT01362764Phase 1
- Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate CancerCompletedNCT01186484Phase 1
- A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01017939Phase 1
- A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT00910754Phase 1
- Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerCompletedNCT00755885Phase 1/2
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate CancerCompletedNCT00600535Phase 1
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyActive, not recruitingNCT00268476Phase 2/3